Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

20141,626 citationsJournal Article

Authors

Elisabeth H. Bel

Sally E. Wenzel

Philip J. Thompson · University of Western Australia

Charlene M. Prazma · Research Triangle Park Foundation

Oliver N. Keene · GlaxoSmithKline (India)

Steven W. Yancey · Research Triangle Park Foundation

Héctor Ortega · Research Triangle Park Foundation

Ian Pavord

Abstract

In patients requiring daily oral glucocorticoid therapy to maintain asthma control, mepolizumab had a significant glucocorticoid-sparing effect, reduced exacerbations, and improved control of asthma symptoms. (Funded by GlaxoSmithKline; SIRIUS ClinicalTrials.gov number, NCT01691508.).

Topics & Keywords

Asthma and respiratory diseases Respiratory and Cough-Related Research Pediatric health and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 13, pp. 1189-1197

DOI: 10.1056/nejmoa1403291

Field-Weighted Citation Impact: 71.52